Cases & Deals

BioMarin acquires Prosensa Holding N.V. for $680 million

Clients BioMarin Pharmaceutical Inc.

Jones Day advised BioMarin Pharmaceutical Inc. in its acquisition of Prosensa Holding N.V., a public, biotechnology company, focused on the discovery and development of RNA-modulating therapeutics for the treatment of rare genetic disorders. The transaction consideration consisted of an up front cash payment of $680 million and achievement of two future regulatory milestones in an aggregate amount equal of $160 million.

In addition to M&A representation, Jones Day provided tax, regulatory, antitrust, employee benefits, and intellectual property advice regarding this transaction.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.